OHSU

Tomasz M. Beer, M.D., F.A.C.P.

Head Shot of Tomasz Beer
Email: 
click here
Office: 
503 494-6594

Background

Dr. Beer’s major research interests include clinical trials, preclinical investigation and risk factors in prostate cancer. His program investigates a broad range of novel agents for prostate cancer, including immune therapies, nutritional supplements, hormonal agents, chemotherapy drugs and target biologic drugs that seek to exploit prostate cancer’s unique vulnerabilities.

Dr. Beer’s clinical research program is tightly linked with laboratory investigations designed to reveal new treatment targets and strategies.


Summary of Current Research

Special Interests:

Hematology and Medical Oncology

Prostate Cancer


Selected Publications

"Chemotherapy-induced monoamine oxidase expression in prostate carcinoma functions as a cytoprotective resistance enzyme and associates with clinical outcomes," PLoS ONE (Vol: 9, Issue: 9, ) - 2014

"Feasibility, acceptability and findings from a pilot randomized controlled intervention study on the impact of a book designed to inform patients about cancer clinical trials," Journal of Cancer Education (Vol: 29, Issue: 1, Page 181-187) - 2014

"Genetic profiling to determine risk of relapse-free survival in high-risk localized prostate cancer," Clinical Cancer Research (Vol: 20, Issue: 5, Page 1306-1312) - 2014

"Molecular pathways and targets in prostate cancer," Oncotarget (Vol: 5, Issue: 17, Page 7217-7259) - 2014

"Patterns and predictors of symptom incongruence in older couples coping with prostate cancer," Supportive Care in Cancer (Vol: 22, Issue: 5, Page 1341-1348) - 2014

 

OHSU Knight Cancer Institute

Visit Our Site

For Healthcare Professionals


Contact

  Email Tomasz Beer

503 494-6594

Memberships & Associations

American College of Physicians Oregon Medical Association American Society of Clinical Oncology American Society of Hematology American Association for Cancer Research Southwest Oncology Group American Urological Association Radiation Therapy Oncology Group